Navigation Links
Study Aims At The Immune System In Patients With Lou Gehrig's Disease

Carolyn Shimek takes cholesterol-decreasing medications like millions of Americans. However she does not have high cholesterol like others//. This is since she is taking part in a different clinical study found only at the Methodist Neurological Institute (NI) to view the benefits of Lipitor on the immune system in patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS).

Physicians at the Methodist NI's MDA/ALS Clinical Center diagnosed the 48-year-old Victoria, Texas resident in 2005. When she learned of this investigator-initiated research, Shimek knew she had to give it a chance.

‘I have a lot to live for - my family and friends,’ said Shimek, a wife, mother of three, and one of 12 siblings. ‘If participating in this study means it will help me or other ALS patients down the road then it's worth it.’

Dr. Ericka Simpson, co-director of Methodist's ALS Clinic, is the primary investigator who oversees this double-blind study in which patients will be randomly assigned to receive the drug or a placebo. Simpson believes the immune system plays an important role in how ALS affects patients.

‘Lipitor has been shown to regulate immune responses that may provide protection in diseases of the central nervous system. Our goal is to determine whether Lipitor has the ability to improve the course of disease progression and quality of life for our ALS patients,’ said Simpson.

Currently, the only FDA-approved drug therapy for ALS is Rilutek. The drug has been shown to modestly improve patient survival, but has no measurable affect on function or the rate of disease progression. ALS is a progressive neurodegenerative disease characterized by degeneration of the upper and lower motor neurons in the brain and spinal cord which stimulate skeletal muscle movement. As more motor neurons die, muscle weakness gets progressively worse. An estimated 30,000 people throughout the U.S. have ALS, and 8,000 new cas es are diagnosed each year.

Source: Neswise
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... When faced ... worried about germs spreading from the seat to her body, and contamination of children ... and effective way to solve this problem that many people face. , The patent-pending ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... ... 09, 2016 , ... The Justin Veatch Fund announced Thursday that ... the film Whispering Spirits and its discussion guide for use by all ... tool in the war against teen drug abuse. NCADD is the oldest anti-addiction ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Research and Markets has announced the addition of ... offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. ... , Japan , Europe , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
Breaking Medicine Technology: